This annual event provides an opportunity for FDA and CMS/CLIA representatives to respond to member questions and present the agency's current thinking on policies, regulations, guidance documents and inspection programs that are relevant to the oversight of blood and HCT/P programs. Questions for the session are submitted in advance to email@example.com. Identify the regulation or recommendation of interest, the specific issue or concern, and any background information, suggestions or proposed solutions to best illustrate your perspective.
At the completion of this session, participants should be able to:
Evaluate existing practices to establish alignment with current regulatory requirements and recommendations
Apply FDA's recommendations in recently issued guidance to industry
Describe FDA's approach for blood and HCT/P policies, regulations and inspection programs